An ischemic stroke happens when blood supply to the brain is blocked, usually by a blood clot or fatty plaque accumulation in the arteries. Due to this obstruction, there is less oxygen and nutrition available, which damages or kills brain cells. About 87% of all strokes are ischemic strokes, which fall into two primary categories, namely, embolic strokes (clots originate from other areas of the body) and thrombotic strokes (clots form in the arteries of the brain). To reduce brain damage and enhance recovery, prompt therapy is essential. The rising prevalence of the condition is anticipated to positively impact the pipeline landscape for ischemic stroke drugs.
Major companies involved in the ischemic stroke treatment market include Amgen Inc., LIB Therapeutics LLC and NC Medial Research Inc., among others.
Leading drugs currently under the pipeline include evolocumab and lerodalcibep, among others.
The increasing cases of ischemic stroke and the rising technological advancements are poised to positively influence the ischemic stroke pipeline landscape.
The Ischemic Stroke Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into ischemic stroke therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ischemic stroke. The ischemic stroke report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The ischemic stroke pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with ischemic stroke treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ischemic stroke.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pathophysiology of an ischemic stroke starts when blood supply to the brain is blocked, frequently because of thromboembolic incidents. As a result, cellular hypoxia and adenosine triphosphate (ATP) depletion occur, upsetting ion homeostasis and depolarizing neurons. Cytotoxic edema is the outcome of too many calcium and sodium ions entering cells. While the penumbra (the area of brain tissue surrounding the ischemic core) contains tissue that can be salvaged, the ischemic core, where blood supply is drastically restricted, undergoes fast cell death. Damage is made worse by inflammatory reactions, which can result in neuronal death and other long-term impairments if left untreated.
The best treatment for acute ischemic stroke is a small molecule, specifically alteplase (also known as recombinant tissue plasminogen activator, or rt-PA). It is a fibrinolytic drug that is administered intravenously to break up clots and replenish blood supply to the brain. Alteplase is still the sole FDA-approved medication for acute ischemic stroke within a certain time frame, even though other medications like heparins (antithrombotic) and anti-inflammatory drugs may be utilized. Although it is currently at the preclinical stage, research is being done on novel compounds like LK-2, which protects neurons by targeting glutamate activity. Further, the rising focus on the development of ischemic stroke emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Globally, ischemic stroke affects approximately 77.19 million individuals, with a notable increase in cases over recent years. In 2020, there were around 7.86 million new cases of ischemic stroke, contributing to significant mortality and disability. The incidence is higher in low- and middle-income countries, where healthcare access is often limited. Women account for about 56% of ischemic stroke cases. Projections indicate that the number of cases may rise to 9.62 million by 2030, highlighting the growing burden of this condition worldwide.
This section of the report covers the analysis of ischemic stroke drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of ischemic stroke drugs undergoing clinical development.
The drug molecule categories covered under ischemic stroke pipeline analysis include recombinant fusion proteins, small molecules, biologics, peptides, polymers, and monoclonal antibodies, among others. The ischemic stroke report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ischemic stroke.
The EMR report for the ischemic stroke drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ischemic stroke therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ischemic stroke clinical trials:
Major drugs currently in the drug pipeline are as follows:
Amgen is developing Evolocumab, a PCSK9 inhibitor, for ischemic stroke prevention. In the Phase 3 of FOURIER trial, adding Evolocumab to statin therapy reduced ischemic stroke risk by 25% compared to a placebo. Building on these findings, the ongoing Phase 4 EVOLVE-MI trial is evaluating the impact of early Evolocumab administration in reducing cardiovascular events, including ischemic stroke, in patients hospitalized for acute myocardial infarction.
Lerodalcibep, developed by LIB Therapeutics LLC, is a novel, subcutaneous PCSK9 inhibitor designed to significantly reduce low-density lipoprotein cholesterol (LDL-C). While primarily targeting hypercholesterolemia and cardiovascular diseases, current clinical trials do not indicate its development for ischemic stroke treatment. Its potent LDL-C-lowering effects may indirectly benefit stroke prevention by addressing atherosclerotic risk factors.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Ischemic Stroke Drug Report provides a strategic overview of the latest and future landscape of treatments for ischemic stroke. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the ischemic stroke pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share